John Orwin

John A. Orwin is the founder of Ambrosia Biosciences, Inc. Current positions include Chairman at AnaptysBio, Inc. since 2023, Chairman at First Tracks Biotherapeutics, Inc., Director at Biotechnology Innovation Organization, Independent Director at Travere Therapeutics, Inc. since 2017, and Venture Partner at Samsara BioCapital LLC since 2024.
Former roles include Chief Executive Officer at Relypsa, Inc. in 2017, President, CEO, CFO & Director at Atreca, Inc. from 2023 to 2024, Chairman at Affymax, Inc. from 2013 to 2014, Chairman at Cargo Therapeutics, Inc. from 2022 to 2025, Chairman at Nested Therapeutics, Inc., Marketing Director-Oncology Division at ALZA Corp., Independent Director at Array BioPharma, Inc. from 2012 to 2019, Independent Director at NeurogesX, Inc. from 2011 to 2013, Marketing Director at Rhone-Poulenc Rorer Pharmaceuticals, Inc. in 1998, Independent Director at Seagen, Inc. from 2014 to 2023, Senior Vice President-BioOncology Business Unit at Genentech, Inc. from 2005 to 2010, Franchise Vice President-Oncology at Johnson & Johnson from 2001 to 2005, Product Manager-Oncology Division at Schering-Plough Corp.
in 1994, Vice President-Marketing at SangStat Medical Corp.
in 2000, Trustee at Cancer Care, Inc., and Vice President-Oncology Franchise at Janssen Biotech, Inc. in 2004.
Education includes an MBA from New York University, an undergraduate degree from Rutgers State University of New Jersey conferred in 1987, and an MBA from The Leonard N Stern School of Business conferred in 1996.